FDA Clears Updated DWI Software for Portable MRI Neuroimaging Device
The new software for the Swoop® Portable MR Imaging system reportedly enhances the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences by 42 percent in comparison to the previous software.
The Food and Drug Administration (FDA) has granted 510(k) clearance to new software for the Swoop® Portable MR Imaging device that may significantly enhance the quality of diffusion-weighted magnetic resonance imaging (MRI) for neurocritical patients.
The new software offers a 42 percent increase in the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences, according to Hyperfine, the manufacturer of the device. The company noted other benefits of the software include additional compensation for subtle patient movements and more uniform imaging for DWI sequences.
Emphasizing the key role DWI imaging plays in facilitating prompt diagnosis of an array of neurological conditions as well as the monitoring of stroke progression, Hyperfine said the updated software will provide a significant advance in care for high-risk populations.
“With this latest software, Swoop system images provide increasingly valuable diagnostic images that can aid clinicians in caring for neurocritical patients,” noted Edward Knopp, M.D., the senior medical director with Hyperfine.
Hyperfine received an FDA 510(k) clearance earlier this month for the device’s updated brain imaging software. The company said the updated DWI software will be available in March 2023.
(Editor’s note: For related content, see “Emerging Deep Learning System May Enhance MRI Assessment of Intracranial Tumors” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
